INTERSTITIAL LUNG DISEASE
Clinical trials for INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Six-year safety check for inhaled lung fibrosis drug begins
Disease control ENROLLING_BY_INVITATIONThis study follows people who were in previous trials of an inhaled medication called treprostinil for progressive lung scarring diseases. It aims to check the long-term safety and side effects of the drug over up to six years. Only people who completed specific earlier studies a…
Matched conditions: INTERSTITIAL LUNG DISEASE
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New inhaler tested for deadly lung pressure disease
Disease control OngoingThis study is testing the safety and side effects of a new dry powder inhaler version of a medication called treprostinil. It involves about 80 adults with pulmonary hypertension, a serious condition of high blood pressure in the lungs, often linked to lung scarring. The main goa…
Matched conditions: INTERSTITIAL LUNG DISEASE
Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Precision radiation offers hope for lung cancer patients too sick for surgery
Disease control OngoingThis study is testing a precise form of radiation therapy for people with early-stage lung cancer who also have a serious lung-scarring disease (ILD) and cannot have surgery. The goal is to see if this targeted radiation can help patients live longer while keeping side effects ma…
Matched conditions: INTERSTITIAL LUNG DISEASE
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug trial aims to slow lung scarring in rare autoimmune disease
Disease control OngoingThis study is testing whether an investigational drug called tulisokibart can safely slow the progression of lung scarring in people with systemic sclerosis, a rare autoimmune disease. The trial involves 154 participants who will receive either the drug or a placebo for 50 weeks …
Matched conditions: INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Extended trial tests inhaled treatment for scarred lungs
Disease control OngoingThis study aims to check the long-term safety of an inhaled powder called TPIP for people with high blood pressure in the lungs linked to lung scarring (PH-ILD). It is open only to people who finished a previous related study. Researchers will monitor side effects and see if the …
Matched conditions: INTERSTITIAL LUNG DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
New inhaled drug tested for deadly combo of lung scarring and high pressure
Disease control OngoingThis study is testing whether an inhaled drug called mosliciguat is safe and effective for people who have high blood pressure in their lungs (pulmonary hypertension) caused by underlying lung scarring (interstitial lung disease). About 135 participants will be randomly assigned …
Matched conditions: INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC
-
New scan tool aims to spot lung scarring more accurately
Diagnosis OngoingThis study is testing a new computer tool that analyzes chest CT scans to help doctors more accurately diagnose the specific type of lung scarring a patient has. Researchers will create the tool using scans from about 300 patients and then test it on scans from 100 more. They wil…
Matched conditions: INTERSTITIAL LUNG DISEASE
Sponsor: Columbia University • Aim: Diagnosis
Last updated Mar 30, 2026 14:33 UTC